Abstract: Certain aspects of this disclosure are generally related to methods for separating a plurality of particles from a fluid. In some embodiments, the fluid comprises one or more polypeptides and a plurality of particles. In some embodiments, the method comprises at least partially denaturing a polypeptide in the fluid to form a denatured polypeptide. In some embodiments, the method comprises separating a mixture of the denatured polypeptide and at least 10% of a plurality of particles from the fluid. Without wishing to be bound by any particular theory, the denaturation of the polypeptide in the fluid may allow for some of the plurality of particles to associate with the denatured polypeptide, and/or agglomerate with the denatured polypeptide. The mixture comprising the denatured polypeptide and the plurality of particles may settle (e.g., precipitate) in the fluid and may therefore be separated from the fluid.

Abstract: Systems, methods, and compositions relating to pretreatment and enzymatic degradation of polymeric materials comprising one or more crystallizable polymers or copolymers are generally described. Certain aspects are directed to methods comprising reacting a polymeric material comprising a crystallizable polymer or copolymer with a reactive agent to produce a pretreated polymeric material and exposing the pretreated polymeric material to a polymer-degrading enzyme. In some embodiments, the reactive agent induces chain extension, branching, and/or cross-linking of the crystallizable polymer or copolymer. In some embodiments, the reactive agent induces chain scissions followed by chain extension, branching, and/or cross-linking of the crystallizable polymer or copolymer.

Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

Abstract: Systems, methods, and compositions relating to pretreatment and enzymatic degradation of polymeric materials comprising one or more crystallizable polymers or copolymers are generally described. Certain aspects are directed to methods comprising reacting a polymeric material comprising a crystallizable polymer or copolymer with a reactive agent to produce a pretreated polymeric material and exposing the pretreated polymeric material to a polymer-degrading enzyme. In some embodiments, the reactive agent induces chain extension, branching, and/or cross-linking of the crystallizable polymer or copolymer. In some embodiments, the reactive agent induces chain scissions followed by chain extension, branching, and/or cross-linking of the crystallizable polymer or copolymer.

Abstract: Systems, methods, and compositions relating to pretreatment and enzymatic degradation of polymeric materials comprising one or more crystallizable polymers or copolymers are generally described. Certain aspects are directed to methods comprising reacting a polymeric material comprising a crystallizable polymer or copolymer with a reactive agent to produce a pretreated polymeric material and exposing the pretreated polymeric material to a polymer-degrading enzyme. In some embodiments, the reactive agent induces chain extension, branching, and/or cross-linking of the crystallizable polymer or copolymer. In some embodiments, the reactive agent induces chain scissions followed by chain extension, branching, and/or cross-linking of the crystallizable polymer or copolymer.

Abstract: Systems and methods are disclosed configured to train an autoencoder using images that include faces, wherein the autoencoder comprises an input layer, an encoder configured to output a latent image from a corresponding input image, and a decoder configured to attempt to reconstruct the input image from the latent image. An image sequence of a face exhibiting a plurality of facial expressions and transitions between facial expressions is generated and accessed. Images of the plurality of facial expressions and transitions between facial expressions are captured from a plurality of different angles and using different lighting. An autoencoder is trained using source images that include the face with different facial expressions captured at different angles with different lighting, and using destination images that include a destination face.

Abstract: The present disclosure provides methods, compositions, kits, and systems for identifying recombinases and cognate site-specific recombinase recognition sites as well as method for using the identified recombinase/recognition site pairs.

Abstract: Systems and methods are disclosed configured to train an autoencoder. A data training set is generated comprising images of different faces. A first autoencoder configuration is generated, comprising a first encoder, and a first decoder. The first autoencoder configuration is trained using dataset images, wherein weights associated with the first encoder and weights associated with the first decoder are modified. A second autoencoder configuration is generated comprising the first encoder and a second decoder. The second decoder is trained using a plurality of images of a first target face. First encoder weights are substantially maintained, and weights associated with the second decoder are modified. An autoencoder comprising the trained first encoder and the trained second decoder is used to generate an output using a source image of a first face having a facial expression, where the facial expression of the first face from the source image is applied to the first specific target face.

Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

Abstract: The present disclosure provides, in some aspects, methods for enhanced protein structure prediction using protein homology discovery and constrained distograms.

Abstract: Systems and methods are disclosed configured to train an autoencoder using images that include faces, wherein the autoencoder comprises an input layer, an encoder configured to output a latent image from a corresponding input image, and a decoder configured to attempt to reconstruct the input image from the latent image. An image sequence of a face exhibiting a plurality of facial expressions and transitions between facial expressions is generated and accessed. Images of the plurality of facial expressions and transitions between facial expressions are captured from a plurality of different angles and using different lighting. An autoencoder is trained using source images that include the face with different facial expressions captured at different angles with different lighting, and using destination images that include a destination face.

Abstract: Systems and methods are disclosed configured to train an autoencoder using images that include faces, wherein the autoencoder comprises an input layer, an encoder configured to output a latent image from a corresponding input image, and a decoder configured to attempt to reconstruct the input image from the latent image. An image sequence of a face exhibiting a plurality of facial expressions and transitions between facial expressions is generated and accessed. Images of the plurality of facial expressions and transitions between facial expressions are captured from a plurality of different angles and using different lighting. An autoencoder is trained using source images that include the face with different facial expressions captured at different angles with different lighting, and using destination images that include a destination face.

Abstract: Systems and methods are disclosed configured to train an autoencoder using images that include faces, wherein the autoencoder comprises an input layer, an encoder configured to output a latent image from a corresponding input image, and a decoder configured to attempt to reconstruct the input image from the latent image. An image sequence of a face exhibiting a plurality of facial expressions and transitions between facial expressions is generated and accessed. Images of the plurality of facial expressions and transitions between facial expressions are captured from a plurality of different angles and using different lighting. An autoencoder is trained using source images that include the face with different facial expressions captured at different angles with different lighting, and using destination images that include a destination face.

Abstract: Systems and methods are disclosed configured to train an autoencoder using images that include faces, wherein the autoencoder comprises an input layer, an encoder configured to output a latent image from a corresponding input image, and a decoder configured to attempt to reconstruct the input image from the latent image. An image sequence of a face exhibiting a plurality of facial expressions and transitions between facial expressions is generated and accessed. Images of the plurality of facial expressions and transitions between facial expressions are captured from a plurality of different angles and using different lighting. An autoencoder is trained using source images that include the face with different facial expressions captured at different angles with different lighting, and using destination images that include a destination face.

Abstract: Systems and methods are disclosed configured to pre-train an autoencoder using images that include faces, wherein the autoencoder comprises an input layer, an encoder configured to output a latent image from a corresponding input image, and a decoder configured to attempt to reconstruct the input image from the latent image. An image sequence of a CGI sculpted and textured face exhibiting a plurality of facial expressions and transitions between facial expressions is accessed. Images of the plurality of facial expressions and transitions between facial expressions are captured from a plurality of different angles. The pre-trained autoencoder is trained using source images that include a CGI face with different facial expressions captured at different angles, and using destination images that include a real face. The trained autoencoder is used to generate an output where the real face in the destination images is swapped with the CGI face, while preserving expressions of the real face.

Abstract: An open sea fish cage includes a fish enclosure, a floatation collar, and a weight ring. The fish enclosure allows water to flow therethrough. The floatation collar engages an inboard portion of the floatation collar, and includes a plurality of floatation segments that are connected by flexible joints to adjacent floatation segments. A weight ring assembly is suspended from an outboard portion of the floatation collar with first tension members. At least most of the fish enclosure is disposed vertically between the floatation collar and the weight ring assembly.

Abstract: The present invention provides compounds of Formula I, for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

Abstract: The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

Abstract: The present disclosure provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. The compounds are generally of formula (I): Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR. Also disclosed are methods of making compounds for formula 8: comprising introducing group E2 into a compound of formula 7: wherein Ar, Z, P, and E2 are defined herein.

Abstract: The present disclosure provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. The compounds are generally of formula (I): Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR. Also disclosed are methods of making compounds for formula 8: comprising introducing group E2 into a compound of formula 7: wherein Ar, Z, P, and E2 are defined herein.